Olavs Hospital” in collaboration with “National Taiwan Normal University” aims to evaluate PSMA-based theranostics as an alternative treatment for patients with recurrent grade 3 and grade 4 gliomas, with an estimated completion date in December 2025 (NCT05644080). This evidence concerns the gene FOLH1 and central nervous system cancer.